# Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

> **NCT02340962** · PHASE2 · COMPLETED · sponsor: **TaiGen Biotechnology Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** TG-2349
- **DRUG:** Ribavirin
- **DRUG:** Interferon Alfa-2a

## Key facts

- **NCT ID:** NCT02340962
- **Lead sponsor:** TaiGen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-08-12
- **Final completion:** 2016-10-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340962, "Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02340962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*